Can a Three-Drug cocktail clear a stubborn lung infection?
NCT ID NCT05906316
First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time
Summary
Researchers are following 100 people newly diagnosed with Mycobacterium avium complex pulmonary disease (MAC-PD) who need standard three-drug antibiotic treatment. The study measures how many patients clear the infection after six months, how their bacterial load changes, and how their symptoms shift. It also tracks whether patients stick to the regimen and whether doctors need to adjust it. The goal is to understand how well guideline-based therapy works in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- guideline-based three-drug antimycobacterial therapy
- What this could lead to
- If the three-drug regimen clears infections as expected, the findings could help doctors refine how they treat MAC lung disease and set realistic expectations for patients.
- What could go wrong
- This is an observational cohort, not a randomized trial, so it cannot prove the drugs cause any particular outcome. Some patients may not clear the infection, and the antibiotics can cause side effects that make it hard to stay on treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2023
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with Mycobacterium avium complex pulmonary disease that (MAC-PD) requires guideline-based three-drug antimycobacterial therapy. MAC is the most common causative species of pulmonary NTM infections.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Newly diagnosed MAC-PD (primary or recurrent) as per the international NTM guideline that requires three-drug antimycobacterial treatment * Signed and dated informed consent Exclusion Criteria: * The participant is in poor general condition where participation in the study cannot be accepted per discretion of the Investigator * The participant has a known or suspected, current drug or alcohol abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the patient * HIV-infection; * Cystic fibrosis; * \>1 month antibiotic treatment for current MAC infection; * \< 6 months between previous antimycobacterial NTM-PD treatment and antimycobacterial treatment for current MAC-PD * Disseminated MAC infection; * Active pulmonary tuberculosis, fungal or nocardial disease requiring treatment; * Active pulmonary malignancy (primary or metastatic) or any other malignancy requiring chemotherapy or radiotherapy within 6 months before screening or anticipated during the study period;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mycobacterium avium complex pulmonary disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
11 sites in 10 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, Denmark
-
Fukujuji Hospital
RECRUITINGTokyo, Japan
-
Hospital Clínic de Barcelona
RECRUITINGBarcelona, Spain
-
Oregon Science and Health University
RECRUITINGPortland, Oregon, 97239, United States
-
Radboud University Medical Center
RECRUITINGNijmegen, 6511LK, Netherlands
-
Rasmus Rude Laub
RECRUITINGHellerup, Denmark
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
-
UZ Leuven
RECRUITINGLeuven, Belgium
-
University Hospital Center Zagreb
RECRUITINGZagreb, Croatia
-
University Hospital Frankfurt
RECRUITINGFrankfurt, Germany
-
University of Calgary
RECRUITINGCalgary, Alberta, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.